Acute Porphyria Drug Database

Monograph

J07BH02 - Rota Virus, Pentavalent, Live, Reassorted
Propably not porphyrinogenic
PNP

Side effects
Fever, diarrhea and vomiting are reported as very common side effects.
Rationale
Based on the pharmacokinetics of the rotavirus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live human-bovine rotavirus reassortants.
Therapeutic characteristics
The rotavirus vaccine is indicated for the active immunization of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection. It is administered orally by a 3-dose regimen given with intervals of at least 4 weeks. The first dose may be given from the age of 6 weeks and no later than 12 weeks. The third (last) dose may be given up to the age of 32 weeks, but preferably before the age of 20-22 weeks.
Metabolism and pharmacokinetics
The rotavirus vaccine is not metabolized by the cytochrome P450 system.

References

# Citation details PMID
*Government bodies
1. European Public Assessment Report, RotaTeq (SPC).European Medicines Agency (EMA).
2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BH or go back.

Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.
Netherlands
RotaTeq · RotaTeq, orale oplossing
Belgium
RotaTeq · RotaTeq sol. buv.
Denmark
RotaTeq
Norway
RotaTeq
Poland
RotaTeq
Luxembourg
ROTATEQ
Iceland
RotaTeq
Finland
RotaTeq
Latvia
RotaTeq
Serbia
RotaTeq · RotaTeq®
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙